Q2 Earnings Forecast for Flora Growth Issued By Roth Capital

Flora Growth Corp. (NASDAQ:FLGC) – Stock analysts at Roth Capital dropped their Q2 2025 earnings per share (EPS) estimates for shares of Flora Growth in a research report issued to clients and investors on Friday, November 15th. Roth Capital analyst W. Kirk now expects that the company will post earnings of $0.02 per share for the quarter, down from their previous forecast of $0.07. The consensus estimate for Flora Growth’s current full-year earnings is ($0.48) per share. Roth Capital also issued estimates for Flora Growth’s Q3 2025 earnings at $0.02 EPS and Q4 2025 earnings at $0.02 EPS.

Separately, Alliance Global Partners reiterated a “neutral” rating on shares of Flora Growth in a report on Thursday, August 15th.

Flora Growth Trading Down 10.7 %

Shares of NASDAQ:FLGC opened at $1.17 on Monday. The company has a current ratio of 1.02, a quick ratio of 0.79 and a debt-to-equity ratio of 0.43. Flora Growth has a 1 year low of $0.70 and a 1 year high of $2.93. The stock has a 50-day simple moving average of $1.46 and a 200-day simple moving average of $1.23.

Hedge Funds Weigh In On Flora Growth

An institutional investor recently bought a new position in Flora Growth stock. XTX Topco Ltd purchased a new position in shares of Flora Growth Corp. (NASDAQ:FLGC) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 18,070 shares of the company’s stock, valued at approximately $28,000. XTX Topco Ltd owned approximately 0.14% of Flora Growth as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 36.01% of the company’s stock.

Flora Growth Company Profile

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.